-
Mashup Score: 8Paper: Reprogramming CLL T-Cell Mitochondrial Fitness Using PI3K Inhibition for Enhancing CAR T-Cell Therapy - 3 month(s) ago
Program: Oral and Poster Abstracts Session: 702. CAR-T Cell Therapies: Basic and Translational: Poster III Hematology Disease Topics & Pathways: Fundamental Science, Research, Translational Research, Immunology, Metabolism, Biological Processes, Molecular biology 1 Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 2 Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 3 Department of Experimental Immunology, Amsterdam
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 4
Program: Oral and Poster Abstracts Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III Hematology Disease Topics & Pathways: Clinical trials, ALL, Adult, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Adverse Events Bijal D Shah, MD 1, Jeremy Pantin, MD 2 *, Karamjeet S Sandhu, MD 3, Elias Jabbour, MD 4, Jae H. Park, MD 5, Paul Shaughnessy, MD 6, Mehrdad Abedi, MD 7 *, Michael R Bishop, MD 8, Daniel J. DeAngelo, MD, PhD 9, Wolfram Brugger, MD 10 *, Martin
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
At #ASH24, Bijal Shah, MD discusses the healthcare resource utilization and costs associated with managing CRS and ICANS in patients with relapsed /refractory adult B-cell acute lymphoblastic leukemia receiving obecabtagene autoleucel. Read more 👉https://t.co/yVMHcQ79Fl… https://t.co/RTW8QtbuuB https://t.co/poQq3iWrnp
-
-
Mashup Score: 7
Program: Oral and Poster Abstracts Session: 619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Poster III Hematology Disease Topics & Pathways: Clinical trials, Research, Clinical Research, Measurable Residual Disease 1 Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 2 Malignant Hematology Department, Moffitt Cancer Center, Tampa, FL 3 Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL 4
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
At #ASH24, David Sallman, MD discusses a prospective evaluation of the impact of measurable residual disease by error corrected next-generation sequencing with CPX-351 in acute myeloid leukemia. Read more: https://t.co/GLeORd6xQR @ASH_hematology #MoffittASH24 https://t.co/3J0NWpxwSL
-
-
Mashup Score: 12
Program: Oral and Poster Abstracts Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III Hematology Disease Topics & Pathways: Adult, Clinical Practice (Health Services and Quality), Drug development, Treatment Considerations, Study Population, Human, Measurable Residual Disease Nelli Bejanyan, MD 1, Hany Elmariah, MD, MS 1, Jongphil Kim, PhD 2 *, Cheryl Cox 3 *, Melissa Lowden 4 *, Xiaofei Song, PhD 2 *, Hien Liu, MD 5, Bin Yu 6 *, Kayla Reid, MS 7 *, Sean J.
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
At #ASH24, Nelli Bejanyan, MD presents the findings of a first-in-human trial using expanded donor gamma delta T cell immunotherapy to prevent acute myeloid leukemia relapse after allogeneic transplantation. Read more: https://t.co/YEXVvJ01c6 @ASH_hematology #MoffittASH24 https://t.co/a91Z9fga0h
-
-
Mashup Score: 8Paper: Patterns of Progression and Outcomes in Multiple Myeloma after Anti-BCMA CAR T-Cell Therapy - 3 month(s) ago
Program: Oral and Poster Abstracts Session: 653. Multiple Myeloma: Clinical and Epidemiological: Poster III Hematology Disease Topics & Pathways: Research, Adult, Clinical Research, Health outcomes research, Plasma Cell Disorders, Diseases, Real-world evidence, Lymphoid Malignancies, Study Population, Human 1 H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 2 Morsani College of Medicine, University of South Florida, Tampa, FL 3 Department of Hematology and Oncology, USF Morsani/H. Lee
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
Tomorrow at #ASH24, join Ziad Abuhelwa, MD (@zabuhelwa) as he highlights the progression patterns and outcomes in multiple myeloma after anti-BCMA CAR T-cell therapy. Read more: https://t.co/e5sQM4t6fO @ASH_hematology #MoffittASH24 https://t.co/dTrXdeLGzF
-
-
Mashup Score: 9
Program: Oral a nd Poster Abstracts Session: 908. Outcomes Research: Myeloid Malignancies: Poster III Hematology Disease Topics & Pathways: Clinical Practice (Health Services and Quality), Diversity, Equity, and Inclusion (DEI) 1 Department of Oncological Sciences, H. Lee Moffitt Cancer Center, University of South Florida, ALBANY, NY 2 Department of Oncological Sciences, H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL 3 H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 4
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
During #ASH24, Faustine Ong, MD (@faustine_ong) discusses disparities in AML survival in the targeted therapy era. Read more: https://t.co/9vtwS7WPUc @ASH_hematology #MoffittASH24 https://t.co/h2WZUDUCZj
-
-
Mashup Score: 17
Program: Oral and Poster Abstracts Type: Oral Session: 655. Multiple Myeloma: Cellular Therapies: Unleashing Cell Therapies Against Myeloma Hematology Disease Topics & Pathways: Research, Clinical trials, Adult, Clinical Research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Study Population, Human Ciara Louise Freeman, PhD, MSc, FRCPC, MRCP 1, Binod Dhakal, MBBS 2, Gurbakhash Kaur, MD, MA 3,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH24 #mmsm 7️⃣ IMMagine-1 Trial-Anitocabtagene autoleucel (CART-ddBCMA) ➡️ https://t.co/t8Nb52lHpi ✅n=58 pts, median FU:10.3 mo ✅ORR:95%, PFS/OS: NR 🛑5% death related to AEs Early follow up- need to follow up for AEs for longer period of time https://t.co/IrAOMgzwpy
-
-
Mashup Score: 7Paper: Clinical Relevance of Subgrouping in TP53 mutated Myelodysplastic Neoplasms: Insights from ICC and Who Classifications - 3 month(s) ago
Program: Oral and Poster Abstracts Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster II Hematology Disease Topics & Pathways: Adult, Research, Genomics, Clinical Research, Hematopoiesis, Diseases, Biological Processes, Myeloid Malignancies, Technology and Procedures, Human, Study Population, Profiling, Pathogenesis, Molecular testing, Pathology 1 Hematopathology and Laboratory Medicine, Moffitt Cancer Center & Research Institute, Tampa, FL 2 Department of Pathology, H. Lee
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
Join Hammad Tashkandi, MD (@hammadnmt) at #ASH24 for a discussion on the clinical relevance in classification methods and the prognostic implications of subgrouping within TP53-mutated myelodysplastic neoplasms as outlined by WHO and ICC. Read more: https://t.co/EkEBWDG7iV… https://t.co/NXIR2GPVev https://t.co/y1Eed4dSXj
-
-
Mashup Score: 12Paper: Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel - 3 month(s) ago
Program: Oral and Poster Abstracts Session: 907. Outcomes Research: Plasma Cell Disorders: Poster II Hematology Disease Topics & Pathways: Research, Adult, Epidemiology, Clinical Research, Plasma Cell Disorders, Health disparities research, Diseases, Real-world evidence, Lymphoid Malignancies, Study Population, Human Lauren C. Peres, PhD, MPH 1 *, Alicia Richards, PhD 1 *, Surbhi Sidana, MD 2, Laura B. Oswald, PhD 3 *, Danai Dima, MD 4, Aimaz Afrough, MD 5, Leyla O. Shune, MD 6, Shonali Midha, MD 7 *,
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
At #ASH24, Lauren Peres, PhD (@LaurenPeresPhD) discusses racial and ethnic differences in outcomes of multiple myeloma patients treated with idecabtagene vicleucel or ciltacabtagene autoleucel. Read more: https://t.co/0xkmrtbbck @ASH_hematology #MoffittASH24 https://t.co/aaq4VPZoiM
-
-
Mashup Score: 13
Program: Oral and Poster Abstracts Type: Oral Session: 653. Multiple Myeloma: Clinical and Epidemiological: Exploring T Cell Redirecting Therapies, Mutation Profiles and Early Relapse Hematology Disease Topics & Pathways: Research, Translational Research, Clinical Practice (Health Services and Quality), Clinical Research, Health outcomes research, Plasma Cell Disorders, Diseases, Real-world evidence, Lymphoid Malignancies, Adverse Events Doris K. Hansen, MD 1, Ciara Louise Freeman, PhD, MSc, FRCPC, MRCP
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
At #ASH24, Doris Hansen, MD highlights discusses a comprehensive analysis of pre-treatment biomarkers associated with toxicity and durable response in idecabtagene vicleucel therapy for relapsed/refractory #MultipleMyeloma patients. Read more: https://t.co/IHpn3uYz9l… https://t.co/wp0s6Jw0Aq https://t.co/nig6iJPDdu
-
Tomorrow at #ASH24, Wael Gamal, PhD presents on reprogramming chronic lymphocytic leukemia T-cell mitochondrial fitness using PI3K inhibition for enhancing CAR T-cell therapy. Read more: https://t.co/EKeIL0Fd08 @ASH_hematology #MoffittASH24 https://t.co/TIxHXw0SPq